Therefore, on the basis of the essential role of BCR-ABL P210 in both CML diagnosis and COVID-19, further exploration of the mechanism behind BCR-ABL P210 level alteration and its use as a bridge to monitor disease progression would be beneficial. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.